Intensity Therapeutics reported third-quarter 2026 results alongside an update on two cancer studies. Patient enrollment and treatment resumed during the quarter in its Phase 2 breast cancer study, while enrollment restarted at a limited number of U.S. sites in its Phase 3 soft tissue sarcoma study.
The company had $8.5 million in cash and cash equivalents at September 30, 2026.
Key details
- INVINCIBLE-3: The Phase 3 study is testing Intensity’s INT230-6 as a standalone treatment against standard care for certain soft tissue sarcomas in patients receiving second- or third-line treatment. New enrollment resumed at a limited number of U.S. sites in the third quarter.
- The study had been paused for funding reasons. In March 2025, Intensity stopped activating sites and enrolling new patients. The trial had enrolled 21 patients at that point; the company continued treating those patients and maintaining the study, while reducing its costs.
- The protocol was revised during the pause. Intensity said it received feedback and recommendations from investigators and sarcoma specialists, which led to protocol modifications.
- INVINCIBLE-4: New enrollment and treatment resumed in the third quarter in this Phase 2 study of presurgical treatment for triple-negative breast cancer.
- Cash position: Cash and cash equivalents totaled $8.5 million at quarter-end.
What changes
The company has restarted patient enrollment in both studies, although INVINCIBLE-3 enrollment is currently limited to a number of U.S. sites. The update describes a return to trial activity after a funding-related pause; it does not report clinical outcomes from either study.